Acquisitions, Investments, and Licenses - Summary of Investments (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014		Dec. 31, 2013
Investment [Line Items]
Investment, available for sale	$ 4,745		$ 4,301
Plus unrealized gains on investments, options and warrants, net	13,120
Less accumulated losses in investees	(20,492)
Investments, net	35,697	[1]	30,653	[1]
Neovasc [Member]
Investment [Line Items]
Ownership at March 31, 2014	6.00%
Investment, equity method	3,798
Underlying equity in net assets	1,558
Fabrus [Member]
Investment [Line Items]
Ownership at March 31, 2014	12.00%
Investment, equity method	750
Underlying equity in net assets	(362)
RXi [Member]
Investment [Line Items]
Ownership at March 31, 2014	17.00%
Investment, equity method	15,000
Underlying equity in net assets	1,841
Pharmasynthez [Member]
Investment [Line Items]
Ownership at March 31, 2014	17.00%
Investment, equity method	11,300
Underlying equity in net assets	6,405
Zebra [Member]
Investment [Line Items]
Ownership at March 31, 2014	19.00%
Investment, equity method	2,000
Underlying equity in net assets	840
Cocrystal/BZNE [Member]
Investment [Line Items]
Ownership at March 31, 2014	16.00%
Investment, equity method	5,476
Underlying equity in net assets	20
Neovasc Options [Member]
Investment [Line Items]
Investment, available for sale	925
Closing share price at March 31, 2014 for investments available for sale	$ 4.10
ChromaDex [Member]
Investment [Line Items]
Ownership at March 31, 2014	1.00%
Investment, available for sale	1,320
Closing share price at March 31, 2014 for investments available for sale	$ 1.83
ARNO [Member]
Investment [Line Items]
Ownership at March 31, 2014	5.00%
Investment, available for sale	2,000
Closing share price at March 31, 2014 for investments available for sale	$ 2.22
Cocrystal Warrants [Member]
Investment [Line Items]
Investment, available for sale	$ 500

[1] As of March 31, 2014 and December 31, 2013, total assets include $6.8 million and $6.7 million, respectively, and total liabilities include $11.4 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.